Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067962 | 0.93 | HDAC3 (0.46) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL16682332 | 0.90 | HDAC3 (0.51) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3141997 | 0.89 | HDAC1 (0.49) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL16682328 | 0.89 | ADRB3 (0.44) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL13767869 | 0.87 | HDAC3 (0.43) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL14002386 | 0.87 | SSTR4 (0.51) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL18067948 | 0.86 | ADRB3 (0.42) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3142415 | 0.86 | MAPT (0.51) | HDAC3HDAC1HDAC2NCOR2MAPT | |
| SCHEMBL2258889 | 0.86 | SSTR4 (0.50) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL4744310 | 0.86 | SSTR4 (0.56) | SSTR4HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020260597-A1 | COMPOSITIONS COMPRISING ENZYME CLEAVABLE LINKER PLATFORMS AND CONJUGATES THEREOF | DANMARKS TEKNISKE UNIVERSITET (DK) | 2020-12-30 | — | — | WO | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-9266864-B2 | VEGFR3 inhibitors | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2016-02-23 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20150225377-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2015-08-13 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
| US-20140080798-A1 | VEGFR3 INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2014-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225377-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | SSTR4 610/4885HDAC3 4356/4885HDAC1 4357/4885 |
| US-20140080798-A1 | VEGFR3 INHIBITORS | FLT4, FLT1, KDR | SSTR4 508/4885HDAC3 3025/4885HDAC1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.